[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100592199":3},{"organization":4,"outcomesModule":7,"designInfo":24,"detailedDescription":30,"studyPopulation":23,"armGroups":31,"interventions":37,"overallOfficials":23,"centralContacts":43,"locations":53,"responsibleParty":67,"collaborators":23,"id":70,"slug":23,"hasResults":71,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":23,"eligibilityCriteria":75,"healthyVolunteers":71,"sex":76,"minAge":77,"maxAge":78,"enrollmentInfo":79,"targetDuration":23,"studyType":82,"phases":83,"briefSummary":85,"conditions":86,"keywords":23,"overallStatus":55,"whyStopped":23,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":98},{"fullName":5,"class":6},"The First Hospital of Jilin University","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":23},[9],{"measure":10,"description":11,"timeFrame":12},"Relapse-Free Survival(RFS)","Defined as the time from enrollment in this study to the occurrence of relapse. For patients without relapse, the time is calculated until death from any cause or the time of the last follow-up","From date of index treatment to death, disease progression, or end of study, whichever came first, assessed up to 36 months.",[14,17,20],{"measure":15,"description":16,"timeFrame":12},"Overall Survival (OS)","Defined as the time from enrollment in this study to death from any cause. If the exact date of death is unknown, the time of death is defined as the last contact date. If the patient is still alive, the last observed time will be used, and the patient's OS will be considered for analysis.",{"measure":18,"description":19,"timeFrame":12},"Cumulative Relapse Rate (CIR)","Defined as the proportion of patients who experience disease relapse from the time of enrollment in this study.",{"measure":21,"description":22,"timeFrame":12},"MRD Negative Conversion Rate","Defined as the proportion of patients who convert to MRD negative among all evaluable patients for efficacy.",null,{"allocation":25,"interventionModel":26,"interventionModelDescription":23,"primaryPurpose":27,"observationalModel":23,"timePerspective":23,"maskingInfo":28},"NA","SINGLE_GROUP","TREATMENT",{"masking":29,"maskingDescription":23,"whoMasked":23},"NONE","This study is designed to be a prospective cohort study conducted at the First Hospital of Jilin University. The target populations of this study are patients with Middle- and High-risk Acute Myeloid Leukemia in the elderly who received intermediate-dose cytarabine in combination with venetoclax for consolidation therapy from June 1, 2025to December 31, 2026. It is expected to enroll 68 subjects in this study. The subjects' data such as demographics and other baseline characteristics, medications, prognosis, will be collected, and statistical analysis of data will be conducted to compare the effectiveness outcome measures",[32],{"label":33,"type":34,"description":23,"interventionNames":35},"Middle-and High-risk Acute Myeloid Leukemia in the Elderly","EXPERIMENTAL",[36],"Drug: Intermediate-dose Cytarabine in Combination with Venetoclax",[38],{"type":39,"name":40,"description":41,"armGroupLabels":42,"otherNames":23},"DRUG","Intermediate-dose Cytarabine in Combination with Venetoclax","Elderly patients with Middle- and High-risk Acute Myeloid Leukemia who received the Intermediate-dose Cytarabine in Combination with Venetoclax at the First Hospital of Jilin University from March 1, 2024 to December 31, 2026.",[33],[44,49],{"name":45,"role":46,"phone":47,"phoneExt":23,"email":48},"Yehui Tan","CONTACT","+8615948027438","yhtan@jlu.edu.cn",{"name":50,"role":46,"phone":51,"phoneExt":23,"email":52},"Yuying Li","+8613944135650","lyying1001@jlu.edu.cn",[54],{"facility":5,"status":55,"city":56,"state":57,"zip":58,"country":59,"countryCode":60,"cosmosGeoPoint":61,"geoPoint":66,"contacts":23},"RECRUITING","Changchun","Jilin","130000","China","CN",{"type":62,"coordinates":63},"Point",[64,65],125.32278,43.88,{"lat":65,"lon":64},{"type":68,"investigatorFullName":45,"investigatorTitle":69,"investigatorAffiliation":5,"oldNameTitle":23,"oldOrganization":23},"SPONSOR_INVESTIGATOR","Professor","100592199",false,"NCT06990321","Effectiveness of Medium-Dose Cytarabine Combined With Venetoclax for Consolidation Therapy in Elderly Patients With Intermediate to High-Risk Acute Myeloid Leukemia","A Single-center, Single-arm, Prospective Clinical Study of Intermediate-dose Cytarabine in Combination With Venetoclax for Consolidation Therapy of Middle- and High-risk Acute Myeloid Leukemia in The Elderly","Inclusion Criteria:\n\n1.Age ≥ 60 years and ≤ 75 years, regardless of gender; 2.Diagnosed with AML (acute myeloid leukemia) according to WHO criteria (non-acute promyelocytic leukemia); 3.Risk stratification as intermediate or high risk based on the ELN (2022) guidelines; 4.Expected survival time ≥ 3 months; 5.Not suitable for allogeneic hematopoietic stem cell transplantation; 6.AML patients who achieve remission with morphologic assessment of bone marrow showing no leukemic involvement after induction therapy; 7.Eastern Cooperative Oncology Group Performance Status (ECOG-PS) score of 0-2; 8.Meeting the following laboratory requirements (performed within 7 days prior to treatment):\n\n1. Total bilirubin ≤ 1.5 times the upper limit of normal for the same age group;\n2. AST and ALT ≤ 2.5 times the upper limit of normal for the same age group;\n3. Serum creatinine \\< 2 times the upper limit of normal for the same age group;\n4. Cardiac ejection fraction within normal limits as determined by echocardiogram. 9.Able to comply with the study visit schedule and understand and adhere to all trial protocol requirements; 10.Able to take oral medications.\n\nExclusion Criteria:\n\nSubjects who meet any of the following criteria shall not be included in this study:\n\n1. Allergic to any drugs included in the trial protocol or drugs with a chemical structure similar to the investigational drug.\n2. Chemotherapy intolerance assessed by Ferrara 2013 criteria prior to enrollment.\n3. Hematologic relapse (bone marrow blasts or immature cells exceed 5%).\n4. Simultaneous diagnosis of other malignant tumors in organs (requiring treatment).\n5. Known or suspected drug abuse or alcohol dependence.\n6. Mental illness or any condition that prevents obtaining informed consent, or inability to comply with the study treatment and examination requirements.\n7. Liver dysfunction (total bilirubin \\>1.5×ULN, ALT\u002FAST \\>2.5×ULN, or liver-involved patients with ALT\u002FAST \\>5×ULN), kidney dysfunction (serum creatinine \\>1.5×ULN).\n8. Active heart disease, defined as one or more of the following:\n\n1\\) History of uncontrolled or symptomatic angina. 2) Myocardial infarction within 6 months prior to enrollment. 3) History of arrhythmias requiring drug treatment or with severe clinical symptoms.\n\n4\\) Uncontrolled or symptomatic congestive heart failure (\\>NYHA class 2). 5) Ejection fraction below the lower limit of normal. 9.Participation in another clinical trial within 30 days. 10.Active infection. 11.The investigator deems the subject unfit for participation in this trial.","ALL","60 Years","75 Years",{"count":80,"type":81},68,"ESTIMATED","INTERVENTIONAL",[84],"PHASE3","A Single-center, Single-arm, Prospective Clinical Study of Intermediate-dose Cytarabine in Combination with Venetoclax for Consolidation Therapy of Middle- and High-risk Acute Myeloid Leukemia in the Elderly",[87,88],"Acute Myeloid Leukemia (AML)","Elderly","2025-08-05",{"date":91,"type":92},"2025-08-08","ACTUAL",{"date":94,"type":92},"2025-06-01",{"date":96,"type":81},"2026-12-31",{"name":45,"class":6},1]